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Abstract 
Eye plaque brachytherapy represents a safe and effective therapeutic approach for choroidal melanoma, combining 
clinical outcomes with an eye and visual preservation. 
As it represents a complex procedure, a specific quality assurance program is strongly suggested to improve pa-
tients and operators safety, and to reduce possible complications linked to surgical procedure and radiation exposure. 
The aim of this paper is to describe the INTERACTS (Interventional Radiotherapy Active Teaching School) guide-
lines for quality assurance in choroidal melanoma interventional radiotherapy (brachytherapy) used in our institution. 
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Purpose 
Ocular melanoma represents the second most com-
mon type of melanoma after cutaneous form. It general-
ly originates from uvea (82.5% of the cases), and is the 
first primary intraocular malignancy with an incidence 
that varies between 2 cases per million in the Southern 
Europe and 8 per million in the Northern Europe [1,2]. 
For its peculiar early clinical presentation (scotomas ac-
companied or not by pain, eye pressure modifications), 
it is generally diagnosed in early stage; however, even 
disease dissemination is not uncommon (5% of cases) 
presenting hepatic metastases close to 90% [3]. Radiation 
therapy has gained a major role in the treatment of this 
disease as described by the COMS (Collaborative Ocular 
Melanoma Study), which showed no survival differenc-
es between patients whose tumors were treated with 125I 
eye plaque brachytherapy and those treated with surgical 
enucleation; however, radiotherapy offers improved vi-
sual preservation and cosmetic outcome [4]. Further ex-
periences have confirmed these observations also by the 
use of different radionuclides (106Ru/Rh or 103Pd) [5,6,7]. 
As the size and location of disease have a crucial role in 
the choice of the clinical management of this tumor, and 
several aspects should be taken into account, a multidis-
ciplinary approach is strongly suggested [7,8,9,10]. Eye 
brachytherapy represents therefore a complex procedure 
that involves a skilled multidisciplinary and multiprofes-
sional team, and requires strict quality assurance (QA) 
protocols to assure optimal clinical results and operator 
safety. Our Institution has developed an internal QA 
handbook about radiation therapy treatments in 2001, 
with several chapters dealing with the different aspects 
of the radiation oncology workflow [11,12]. A specific 
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chapter for eye plaque brachytherapy procedures has 
been added in 2006, including the detailed description 
of treatment procedures (before, during, and after), and 
treatment related documentation (forms) as well the nec-
essary checklists. The first principle of the QA procedures 
is their ‘traceability’, which is the possibility to identify, 
through the signature of specific reports, the operator 
who has realized their single steps. 
The second one is the ‘verifiability’ of the performed 
procedures that is based on the use of quality indicators, 
demonstrating the adherence to predefined QA standards. 
Recently, we have proposed eye brachytherapy QA 
guidelines in the frame of the Interventional Radiothera-
py Active Teaching School (INTERACTS), which has its 
mission in the education and research in interventional 
radiotherapy [13]. 
The aim of this paper is to describe the INTERACTS 
guidelines for QA in choroidal melanoma interventional 
radiotherapy (brachytherapy) workflow, which is articu-
lated in five main issues (Figure 1). 
Step 1. Multidisciplinary tumor board: a case  
presentation and treatment procedure decision 
The published American Brachytherapy Society 
(ABS) consensus guideline for eye plaque brachyther-
apy recommends to refer choroidal melanoma patients 
to experienced sub-specialty centers with high amount 
of treated patients per year, as differences in procedural 
volume have been reported as a significant predictors of 
risk adjusted mortality [7,8,9]. 
Our Institution treats on average 40 choroidal mela-
noma cases per year, and represents a national reference 
center for this treatment. From December 2006 to Decem-
ber 2016, we have treated 417 choroidal melanoma pa-
tients with the use of 106Ru/Rh (343 cases) plaques and 
125I (74 cases) treatments. Since the first eye plaque im-
plant, an internally developed QA protocol has always 
been followed, and no major clinical relevant incidents 
have ever been registered. 
Multidisciplinary tumor board 
The clinical practice workflow includes the presen-
tation of the cases in a weekly multidisciplinary tumor 
board (MTB), which includes an ophthalmologist skilled 
in plaque placement surgery, as well as a radiation oncol-
ogist and a physicist familiar with interventional radio-
therapy applications [7,8,9]. A medical oncologist is also 
involved in the discussion in case of metastatic presen-
tation of disease. When computed tomography (CT) or 
magnetic resonance imaging (MRI) are available, images 
are discussed with a radiologist (Table 1). 
Multidisciplinary tumor boards allow for more effec-
tive control of patient’s workflow, optimizing the role of 
the different figures involved and assuring a more accurate 
and complete disease staging and therapy indication with 
initial evidence of improvements in clinical outcome [10]. 
The ophthalmologist presents the patient’s history and re-
cords to the other MTB members. General physical exam, 
visual acuity and eye pressure, slit lamp and ophthalmo-
scopy, ultrasound (US) A and B-scans, angiography, and 
wide field fundus photography findings are reported and 
discussed [7,14,15,16,17,18,19,20,21,22,23]. Histopathologi-
cal data are not mandatory and biopsy can be substituted 
with a clinical diagnosis by an ophthalmologist skilled in 
eye melanoma, based on different exams with a false posi-
tive rate below 1-2% for expert personnel [24]. 
Gross tumor volume (GTV) definition 
The ophthalmologist provides a detailed diagram of 
fundus oculi with tumor margins orientation; the dis-
tance from optic nerve and fovea are reported. Basal di-
1.  Multidisciplinary tumor board: case presentation  
and treatment choice
2.  Treatment planning: plan calculation and pre-plan approval
3. Source preparation: applicator loading and sterilization
4. Surgery: Plaque implantation
5. Treatment and plaque removal
Fig. 1. Eye plaque brachytherapy workflow main steps
Table 1. Multidisciplinary tumor board composition 
Multidisciplinary team member Presence Role
Ophthalmologist Always Introduces patient’s and lesion’s characteristics and defines the 
gross tumor volume (GTV)
Radiation oncologist Always Confirms the treatment indication to eye brachytherapy, defines 
the clinical target volume (CTV) and planning target volume (PTV), 
chooses the most appropriate radionuclide along with physicist, 
and prescribes the dose to the apex 
Physicist Always Performs treatment planning, and is involved in radionuclide 
choice 
Medical oncologist Only in some cases Discussion in case of metastatic presentation of disease 
Radiologist Only in some cases Discussion in case of CT or MRI availability 
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ameters and apex height of the disease are also carefully 
measured for gross tumor volume (GTV) definition. Ul-
trasound scans have a crucial role in disease extension 
measurement, and for a reliable evaluation of the GTV, 
the use of both A and B-scans is strongly recommended. 
Tumor diameters are defined with B-scans while disease 
height assessment is evaluated with A-scans, and their 
information cannot be replaced by other US techniques, 
even if with higher nominal resolution [14]. 
Interventional radiotherapy (brachytherapy) 
indication 
For patients with melanomas > 5 mm apex distance, 
a systemic staging is usually requested. 
We consider patients eligible for primary eye 
brachytherapy if choroidal melanoma average dimensions 
(thickness, 2-9 mm) and maximum diameters < 16 mm 
are present without systemic disease. The treatment of 
diseases that do not meet these parameters are to be dis-
cussed in detail by the MDT to consider the possibility 
to integrate therapeutic and palliative purposes of the 
treatment without excluding a priori brachytherapy. The 
reasons of each decision are documented in details in the 
patient’s chart. 
In case of systemic diseases or in ocular metastases, 
we consider eye brachytherapy as a palliative treatment, 
in order to prevent eye pain due to tumor caused second-
ary glaucoma. 
Clinical target volume definition 
The radiation oncologist then confirms the treat-
ment indication for eye brachytherapy. The radiation 
oncologist defines the clinical target volume (CTV) and 
prescribes the dose to the tumor apex. This volume rep-
resents a safety margin extension of 1-2 mm in all direc-
tions, accounting for microscopic disease spread along 
uvea and sclera. 
The CTV thickness is defined taking into account the 
tumor thickness, usually read on B-scan sonography im-
ages with a 1 mm extension for the sclera. A case by case 
defined planning target volume (PTV), extra safety mar-
gin can be added by the radiation oncologist in case of 
uncertainties in tumor delineation and/or plaque local-
ization [24,25]. 
Radionuclide definition and dose prescription
Considering the aforementioned dimensions, the ra-
diation oncologist along with the physicist defines the 
most appropriate radionuclide for plaque loading. In our 
Institution, we use 106Ru/Rh plaques for lesions less than 
5 mm in thickness, as they allow more simple radiopro-
tection procedures with better toxicity profile (especially 
in terms of cataract and retinopathy), and overall surviv-
al and local control outcomes comparable to 125I seeds, 
which are generally used for thicker lesions [26,27]. 
The prescription dose suggested by the GEC ESTRO 
is 100 Gy to the apex for 106Ru/Rh, and 70-150 Gy to the 
apex for 125I with dose rates between 50-100 cGy/h, while 
the American Brachytherapy Society suggests a prescrip-
tion dose of 70-100 Gy to the apex with a dose rate not less 
than 60cGy/h for both isotopes [24]. 
In our Institution, the dose is prescribed to the apex 
with a total prescription of 100 Gy for 106Ru/Rh, and 
85 Gy for 125I with dose rate > 50 cGy/h. 
If consensus is reached on the eye brachytherapy in-
dication and isotope choice, the multidisciplinary group 
proceeds to phase 2: treatment planning. 
Step 2. Treatment planning: plan calculation  
and pre-plan approval 
The physicist calculates a provisional treatment plan 
(pre-plan) using a dedicated 3D calculation software 
(Plaque SimulatorTM, Bebig, Germany), and performing 
Fig. 2. Example of 3D treatment planning (Plaque SimulatorTM, Bebig, Germany)
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an independent check of treatment time by manual cal-
culation. 
Plaque planning provides a graphical distribution of 
dose, dose volume histogram (DVH) of the therapy vol-
umes (target and organs at risk), and dose rate informa-
tion (Figure 2). 
Plaque arrangements can be different varying radionu-
clides, source strengths, and ring dimensions [28]. 
In our Institution, plans are approved when at least 
95% of target volume is covered by the prescribed dose. 
An indicative maximal constraint of 1000 Gy is consid-
ered for the sclera [24] (Table 2). 
The main advantage of 3D planning is represented 
by the possibility to identify eventual peripheral un-
derdosed target areas that do not allow plan delivery: 
in these cases, patients could be addressed to adjuvant 
transpupillary thermotherapy (TTT) or photodynamic 
therapy (PDT) [29,30]. 
Independent check 
Our QA protocol requires an independent check of 
the treatment workflow at this level. 
The internal guidelines used in our Institution define 
the independent check as the revision of the completeness 
and accuracy of accomplished procedures performed by 
an operator with adequate professional skills, who has 
not been directly involved in the treatment process [31]. 
Main aim of the independent check process is to guaran-
tee the correct flow of treatment procedures. A physicist 
proceeds with the independent check of the dosimetrical 
and geometrical parameters of the pre-plan, and a radi-
ation oncologist performs a medical independent check 
verifying all therapy passages and gives his authoriza-
tion for the treatment to proceed. The independent check 
is done following a check list comprehending the veri-
fications of several parameters: patient name, ocular US 
report, therapy volume measurement (GTV-CTV-PTV), 
implant notes, correspondence between US findings and 
treatment plan, plaque code, correspondence between 
the prescribed and the planned dose, and presence of 
physics independent check. 
Informed consent 
At this time, the total treatment time is calculated: 
surgery and patient admission to the wards are sched-
uled accordingly. A double copy of patient’s informed 
consent is then collected: one copy is to be maintained in 
brachytherapy ward records, while the second one is to 
be stored in ophthalmology archives. Informed consent 
is collected by ophthalmologist and radiation oncologist 
at the same time. 
Step 3. Source preparation: applicator loading 
and sterilization 
After the pre-plan approval and following the in-
dependent checks, radiation therapy technician (RTT) 
proceeds with the preparation of the chosen 106Ru/Rh 
plaque or arranges the selected seeds configuration for 
125I treatment. Following the pre-treatment plan indica-
tion, the RTT places the seeds inside a silicone support 
and covers with a protection plaque (Figure 3). 
Table 2. Planning tips for radionuclides used in our Institution 
Source Prescription doses Treatment planning constraints Plan acceptance criteria
106Ru/Rh 100 Gy (> 50 cGy/h) Sclera < 1000 Gy > 95% target coverage
125I 85 Gy (> 50 cGy/h) Sclera < 1000 Gy > 95% target coverage
Fig. 3. Seeds configuration in the silicone support (left) following pre-treatment plan indications (right)
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The manipulation of the seeds requires particular at-
tention, and specific rules need to be followed in order to 
avoid seed damage as operating errors can cause a pos-
sible contamination [32]. Our internal QA protocol sug-
gests therefore not to clamp the seed too strongly during 
its manipulation, as these operations can damage its sur-
face. A contamination check is mandatory before treat-
ment and it can be performed in two ways: a water test 
(immersing the plaque in water) and with the smear test 
(gently brushing the applicator with a cotton swab). Both 
water and swab are then checked for contamination to 
confirm the absence of leaking seeds (Figure 4). 
Thanks to this procedure, in our experience, one treat-
ment out of 74 had to be re-planned due to inadequate 
source preparation with consequent contamination (error 
detected by contamination test). 
The plaques then undergo the sterilization process 
(autoclave for 106Ru/Rh plaques and gas plasma for 125I). 
During this process, the pressure and temperature could 
temporarily modify the silicone insert, so that the seeds 
can move from the original position (Figure 5). 
For this reason, the seeds configuration needs to al-
ways be checked after the sterilization process and before 
the surgical implant. In our experience, we detected one 
case of seeds dislodgment after sterilization out of 74 
performed procedures. After this incident, we have mod-
ified the QA procedures and introduced the fixation of 
Fig. 4. 125I source contamination check with water (top) and swab (bottom) test
Fig. 5. During the sterilization process, the pressure and 
temperature can temporarily modify the silicone insert, so 
that the seeds can move away from the original position. 
Example of seeds dislodgment after sterilization
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the silicone support to the plaque before sterilization with 
a proper amount of a glue (Figure 6). After introduction 
of this procedure, no errors in the configuration of seeds 
after sterilization have been observed. 
Following the QA procedures, the applicator is ready 
for surgical implantation. 
Step 4. Surgery: plaque implantation 
The implantation of the plaque is performed by oph-
thalmologist together with radiation oncologist, general-
ly in local anesthesia. 
Surgical technique 
The surgical approach consists of a conjunctival perito-
my with disease quadrant exposure (Figure 7A) and local-
ization of tumor (GTV) borders by transillumination of the 
eye, by placing an optic fiber light at 180 degrees from the 
tumor [24] (Figure 7B). Then, ophthalmologist proceeds 
with the tumor border marking (using a sterile marking 
pen) and adding a safety margin of 2-3 mm (Figure 7C). 
Considering this so defined area, a sterile dummy appli-
cator of a proper size and shape is positioned and fixed 
with loose sutures to the overlying sclera (Figure 7D). 
These procedures contribute in minimizing the exposure 
of the personnel present in the operating theatre. 
When the reliability of the implantation (tumor cov-
erage) will be confirmed (even by transillumination pho-
tography and/or through US if necessary), the dummy 
will be replaced by the loaded applicator and the scleral 
sutures have to be tightened (Figures 7E and 7F). 
Surgical approach recommendations 
The use of US positioning confirmation is strongly 
suggested, especially for posterior lesions, as recent ex-
periences show a relative local failure rate of 0% when it 
is performed [33]. During surgical procedures, the plaque 
needs to be manipulated by following specific rules. 
An incorrect handling of 125I plaque can cause a dis-
placement of the seeds: in our experience, this incident 
occurred once during procedure. After this episode, strict 
rules were introduced regarding plaque handling; we 
advise to manipulate it from peripheral lugs on the shell 
while avoiding touching the silicone insert. No other dis-
placement incidents have been detected since the intro-
duction of this procedure. 
The risk of contamination is present also for 106Ru/Rh 
plaques, as they could be scratched during positioning. Our 
QA program suggests to use normal clamps to hold the 
plaque from lugs, and to prefer clamps covered by plastic 
material to touch the plaque in the operating theatre. 
This recommendation is active in our institution since 
the first implant, and no contamination has ever been de-
tected. 
Post-surgery procedures 
The exact positioning time of the plaque is recorded 
and communicated to physicist for treatment time confir-
mation and removal time calculation. 
The patient is then transported to the ward with ap-
propriate protection shell on the treated eye, lying in 
a bed pulled from the foot side (to maximize the distance 
between the source and the stretcher bearer). Elevators 
and corridors of the scheduled itinerary are left free in 
advance to avoid people accidental irradiation. 
Step 5. Treatment period and plaque removal 
Patients undergoing eye plaque brachytherapy with 
106Ru/Rh are admitted to ophthalmology ward, while pa-
tients implanted with 125I are admitted in the radio-pro-
tected interventional radiotherapy ward, in which a ra-
diation shielded single room is available. In both cases, 
an appropriate support therapy is prescribed by oph-
thalmologist and by radiation oncologist. During the 
hospitalization, patient undergoes three visits per day, 
and general conditions (e.g. vital parameters or pain) 
are registered. Visitors are not allowed in the protected 
brachytherapy ward and the patient is requested to wear 
a protection shell on the eye when the personnel enters 
in the room. 
The typical duration of an implant in situ varies be-
tween 1 and 7 days [34]. At the end of the calculated 
treatment time, the plaque is removed with a new surgi-
cal procedure: 106Ru/Rh plaques’ integrity and 125I seeds 
number and status are checked. Following the plaque re-
Fig. 6. Procedure to reduce the risk of seeds dislodgment after sterilization: a proper amount of a glue is used to fix the silicone 
support to the plaque before sterilization
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moval, a contamination check of the plaque by smear test 
and of patient’s orbit is always performed (Figure 8). 
The patient is then discharged with scheduled fol-
low-up visit dates, and is asked to fill out a satisfaction 
questionnaire about overall treatment. 
Advantages and indicators of the INTERACTS 
QA guidelines 
The main advantages linked to the implementation of 
the INTERACTS QA guidelines in choroidal melanoma 
interventional radiotherapy are represented by the facili-
tation of the management of high amount of patients for 
such a complex procedure that requires a well-structured 
workflow, which combines surgical and radiotherapeutic 
skills. 
The use of these QA guidelines could furthermore re-
duce legal arguments and medico-legal issues, thanks to 
the aforementioned principles of traceability and verifi-
ability of single steps. The traceability of all procedures 
is granted by the use of QA modules, in which all steps 
are described in detail and involved personnel is clearly 
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defined. Each of the involved figure places a signature in 
the specific field of dedicated form, once a step has been 
successfully accomplished. 
In this context, the main quality indicators can be 
identified in: 1. Planned independent checks (medical 
and physical); 2. Contamination tests. 
A third advantage of the application of these guide-
lines is related to their educational role, helping residents 
and in training personnel in optimizing their knowledge 
about the procedure and professional skills, imparting 
the importance to always operate as per QA frame. 
Furthermore, eye melanoma is an uncommon disease: 
a multicentric data collection and interdisciplinary elec-
tronic database could therefore offer an efficient tool to 
produce valuable evidences and improve QA procedures 
through data sharing among subspecialty centers [35,36]. 
Conclusions 
Eye plaque brachytherapy is a highly specialized ther-
apy that needs particularly trained personnel in experi-
enced high workload centers. Due to the numerous figures 
involved in this kind of treatment, an accurate coordina-
tion between team members is required. Quality assurance 
protocols are strongly suggested to monitor the workflow, 
prevent accidents, and avoid complications. The adoption 
of the proposed INTERACTS guidelines for QA in choroi-
dal melanoma interventional radiotherapy (brachythera-
py) is therefore strongly suggested for eye brachytherapy 
treatments, as it offers high level of patient and operator 
safety as well as best possible clinical outcomes with a neg-
ligible rate of clinically relevant complications. 
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